Evolva Holding SA announces that it has entered into an agreement with Cargill to jointly develop and commercialize fermentation-derived steviolglycosides.
Evolva Holding SA announces the start of its capital increase and will raise up to CHF 31.3 million by means of a rights issue to existing shareholders.
Sequana Medical announces that its ALFApump® System has received German Neue Untersuchungs und Behandlungsmethode (NUB) approval which allows participating hospitals to receive reimbursement for innovative new products.
Aleva Neurotherapeutics SA closes EUR 9.5 Mio. (CHF 10.1 Mio.) Series A financing round with BioMedInvest II LP as co-lead investor.
Sequana Medical today announced that it has received CE Mark approval for the commercial sale of its ALFApumpTM System. Furthermore, the team gets strengthen by Dr. Farzana Malik as Vice President of Market Access and Reimbursement.
Anergis SA closed its Series A financing round of CHF 18 Mio. with BioMedInvest II LP as co-lead-investor.
NovaShunt AG raises CHF 23.7 Mio. in a Series B financing co-led by BioMedInvest II LP.
Evolva SA announced that it has initiated a multiple ascending dose Phase I clinical study with an extended release oral formulation of EV-077.
Evolva announced that a group of core shareholders have agreed to partially extend the lock-up on their current holdings through a coordinated sale of shares.
BioMedPartners announce the final closing of BioMedInvest II LP, its second healthcare venture capital fund, at CHF 106 Mio. and strengthens its management team.
BioMedPartners erhöht das Volumen des BioMedInvest II LP Funds auf CHF 106 Mio. und verstärkt ihr Management Team um Dr. Karl Deres als neuen Venture Partner.
Curetis AG closed its Series A financing round of EUR 18.5 million (CHF 27.9 Mio.) with BioMedInvest II LP as co-lead-investor.
Activaero GmbH announces the closing of a Series A financing totalling EUR 10.7 Mio. (CHF 16.2 Mio.) with BioMedInvest II LP as lead-investor.
Evolva SA announces first closing of its Series B financing round of CHF 28 Mio. with BioMedInvest-II LP as co-investor.
BioMedPartners raise 95 Million for new healthcare venture fund.
